CoChat

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer

Open access

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; none of the 58 sources its claims cite is checked for support yet.

Abstract

Epidermal growth factor receptor (EGFR) is a well-exploited therapeutic target in metastatic colorectal cancer (mCRC). Unfortunately, not all patients benefit from current EGFR inhibitors. Mass spectrometry–based proteomics and phosphoproteomics were performed on 30 genomically and pharmacologically characterized mCRC patient–derived xenografts (PDXs) to investigate the molecular basis of response to EGFR blockade and identify alternative drug targets to overcome resistance. Both the tyrosine and global phosphoproteome as well as the proteome harbored distinctive response signatures. We found that increased pathway activity related to mitogen-activated protein kinase (MAPK) inhibition and abundant tyrosine phosphorylation of cell junction proteins, such as CXADR and CLDN1/3, in sensitive tumors, whereas epithelial-mesenchymal transition and increased MAPK and AKT signaling were more prevalent in resistant tumors. Furthermore, the ranking of kinase activities in single samples confirmed the driver activity of ERBB2, EGFR, and MET in cetuximab-resistant tumors. This analysis also revealed high kinase activity of several members of the Src and ephrin kinase family in 2 CRC PDX models with genomically unexplained resistance. Inhibition of these hyperactive kinases, alone or in combination with cetuximab, resulted in growth inhibition of ex vivo PDX-derived organoids and in vivo PDXs. Together, these findings highlight the potential value of phosphoproteomics to improve our understanding of anti-EGFR treatment and response prediction in mCRC and bring to the forefront alternative drug targets in cetuximab-resistant tumors.

Overview

CoChat Summary

TL;DR

Mass-spectrometry proteomics and phosphoproteomics of 30 metastatic colorectal cancer patient-derived xenografts identified phosphosite and protein signatures distinguishing cetuximab-sensitive from cetuximab-resistant tumors and nominated hyperactive kinases, including EPHA2/Src family kinases, as targets in genomically unexplained resistance. Dasatinib alone or with cetuximab inhibited growth in CRC0161 organoids and blocked tumor growth in CRC0166 PDX tumors in vivo.

Key findings

  • In 30 mCRC PDXs (10 cetuximab-sensitive, 20 cetuximab-resistant), the proteome contained 5287 proteins and the phosphoproteome contained 13,110 class-I phosphosites (8973 pSer, 1066 pThr, 3073 pTyr) on 15,095 phosphopeptides from 5207 phosphoproteins, including 255 kinases of which 53 were tyrosine kinases. Differential comparisons yielded 53 phosphosites and 53 proteins for CS vs CR-ALL, 75 phosphosites and 49 proteins for CS vs CR-MUT, and 17 phosphosites and 72 proteins for CS vs CR-WT (P < 0.01, fold change > 1.5).
  • Sensitive tumors showed increased tyrosine phosphorylation of cell junction proteins such as CXADR and CLDN1/3, enrichment of OXPHOS, Myc targets, and adipogenesis, and enrichment of signatures related to MEK1/2 inhibitor U0126 and p38 MAPK inhibitor losmapimod. Resistant tumors showed enrichment of EMT, AKT1, and MAPK signaling; PTM-SEA found TSLP and ABL1 pathways enriched in resistant tumors (FDR P < 0.05), and CXADR RNA expression was significantly higher in CS models in both RNA400 and RNAsub comparisons (P < 0.05).
  • INKA analysis confirmed driver activity of ERBB2, EGFR, and MET in cetuximab-resistant tumors with corresponding gene amplifications, and revealed high Src and ephrin kinase family activity in two CRC PDX models with genomically unexplained resistance (CRC0161 and CRC0166). Dasatinib reduced viability in CRC0161 organoids in the micro- to nanomolar range but not in control models CRC0196 and CRC0254; low-dose cetuximab (0.7 μg/ml, ~5 nM) plus dasatinib (5 nM) impaired viability whereas either alone was ineffective, and high-dose cetuximab (140 μg/ml, ~1000 nM) reduced viability by only about 40% versus about 80% for dasatinib (1000 nM).
  • In vivo, CRC0166 PDX tumors treated for 3 weeks showed no control by dasatinib alone, only retarded growth with cetuximab alone, and tumor volume increased by 40% on average; the combination of dasatinib and cetuximab completely blocked tumor growth, with a significant advantage in tumor volumetric reduction compared with single-agent cetuximab (P = 0.0377).

Methods

  • Label-free LC-MS/MS proteomics and phosphoproteomics were performed on 30 genomically characterized mCRC PDX tumors (10 CS, 20 CR), using pTyr immunoprecipitation, TiO2-based global phosphopeptide enrichment, and protein-expression profiling; biological and technical replicates were measured for reproducibility, and seven samples were excluded from TiO2 data due to technical failure or high variation/low peptide yield.
  • Group comparisons were made for CS vs CR-ALL, CS vs CR-MUT, and CS vs CR-WT using limma for phosphosite intensities and a beta-binomial test (ibb) for protein expression, with filters of P < 0.01, fold change > 1.5, and >50% data coverage in at least one group; downstream analyses included GSEA, PTM-SEA, STRING/Cytoscape network analysis, MCL clustering, and single-sample INKA kinase activity ranking.
  • Functional validation used organoids derived from PDX models CRC0161, CRC0196, and CRC0254 for CellTiter-Glo viability assays with one-way ANOVA, and in vivo PDX experiments in CRC0166 treated for 3 weeks with cetuximab (20 mg/kg intraperitoneal, twice weekly), dasatinib (50 mg/kg oral gavage, daily), or the combination, with tumor volume measured by caliper.

Limitations

  • Stated: the analyses focused on static interrogation of phosphoprotein and protein biomarkers in treatment-naïve PDX tumors and correlated results with cetuximab outcome, so dynamic changes over therapy were not assessed; the association between cetuximab resistance and high EPHA2 and Src family kinase activity was not validated in clinical samples from therapeutically annotated mCRC patients; CRC0161 organoid results could not be confirmed in vivo because it failed to re-engraft as PDX, and CRC0166 could not be grown as organoids but was tested in vivo.
  • Evident from the text: functional validation of the dasatinib hypothesis rests on two genomically unexplained resistant models (CRC0161 and CRC0166), limiting broader generalizability, and the clinical relevance of the nominated kinase targets remains untested in patient samples.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abm3687

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 39 Not checked · 108 Own results and interpretations

67 more claims

Create a free account to see all 147 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 46
  • Probably not a substantial claim. 36

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 63 references

Cited by

See all 39

Metadata

Authors
Beekhof, R., Bertotti, A., Böttger, F., Vurchio, V., Cottino, F., Zanella, E. R., Migliardi, G., Viviani, M., Grassi, E., Lupo, B., Henneman, A. A., Knol, J. C., Pham, T. V., de Goeij-de Haas, R., Piersma, S. R., Labots, M., Verheul, H. M. W., Trusolino, L., & Jimenez, C. R.
Affiliations
  • Amsterdam University Medical Centers (NL)
  • Candiolo Cancer Institute (IT)
  • The Netherlands Cancer Institute (NL)
  • Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.
  • Erasmus MC (NL)
Venue
Science Translational Medicine
Published
2023-08-16
Volume
15
Issue
709
Pages
eabm3687-eabm3687
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W4385857908
Cited by
39
References
62
Citations by year
2026: 14 · 2025: 14 · 2024: 11
FWCI
4.59
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Science Translational Medicine (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders
  • Cancer Research UK (22795)
  • Ministero della Salute
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (91116017, 22802)
  • Associazione Italiana per la Ricerca sul Cancro (AIRC5x1000, 22802, 21091, 20697, 22795)
  • Cancer Center Amsterdam
  • Horizon 2020 Framework Programme (731105 EDIReX, 754923, 731105)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
EGFR inhibition, cetuximab resistance, metastatic colorectal cancer, patient-derived xenografts, phosphoproteomics, tyrosine phosphorylation, MAPK signaling, Akt signaling, epithelial-mesenchymal transition, ERBB2, MET, Src family kinases, cell junction proteins, organoids, drug resistance markers, combination therapy
MeSH terms
Cetuximab, Antineoplastic Agents, Colonic Neoplasms, Humans, Phosphoproteins, Phosphorylation, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Proteome, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer. https://app.cochat.ai/papers/10.1126/scitranslmed.abm3687
The paper
Beekhof, R., Bertotti, A., Böttger, F., Vurchio, V., Cottino, F., Zanella, E. R., Migliardi, G., Viviani, M., Grassi, E., Lupo, B., Henneman, A. A., Knol, J. C., Pham, T. V., de Goeij-de Haas, R., Piersma, S. R., Labots, M., Verheul, H. M. W., Trusolino, L., & Jimenez, C. R. (2023). Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abm3687

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.